
Last update at 2026-06-04T15:35:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
| Income before tax | -1.14200M | 39.01M | 6.93M | -22.32200M | 28.05M |
| Minority interest | - | - | - | - | - |
| Net income | -1.17000M | 38.88M | 6.81M | -22.47300M | 27.89M |
| Selling general administrative | 0.97M | 1.13M | 1.56M | 1.22M | 1.07M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 14.38M | 40.14M | 8.49M | -21.10400M | 29.12M |
| Reconciled depreciation | - | - | - | - | - |
| Ebit | - | 37.90M | - | -17.28100M | 28.20M |
| Ebitda | -0.02100M | 39.55M | 6.93M | -21.65900M | 28.05M |
| Depreciation and amortization | - | 1.66M | - | - | - |
| Non operating income net other | - | - | - | - | - |
| Operating income | -0.02100M | 39.55M | 6.93M | -21.65900M | 28.05M |
| Other operating expenses | 18.71M | 3.33M | 1.56M | 1.22M | 1.07M |
| Interest expense | 1.94M | 2.20M | 1.24M | 0.66M | 0.22M |
| Tax provision | 0.03M | 0.14M | 0.12M | 0.15M | 0.16M |
| Interest income | 0.23M | 0.22M | 0.02M | 0.00000M | 0.00000M |
| Net interest income | -1.71200M | -1.98000M | -1.21900M | -0.66300M | -0.21800M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.03M | 0.14M | 0.12M | 0.15M | 0.16M |
| Total revenue | 18.69M | 42.34M | 8.49M | -21.10400M | 29.12M |
| Total operating expenses | 14.40M | 1.13M | 1.56M | 1.22M | 1.07M |
| Cost of revenue | 4.30M | 2.20M | - | - | 2.97M |
| Total other income expense net | -1.12100M | -0.54200M | - | -0.66300M | -0.21800M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -1.17000M | 38.88M | 6.81M | -22.47300M | 27.89M |
| Net income applicable to common shares | - | - | - | -22.47300M | 27.89M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
| Total assets | 284.04M | 308.15M | 304.87M | 326.92M | 347.83M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | -15.04600M | 0.11M | - | - | - |
| Total liab | 34.63M | 25.89M | 34.55M | 42.03M | 24.06M |
| Total stockholder equity | 249.41M | 282.26M | 270.32M | 284.89M | 323.77M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | -29.60700M | -22.82700M | -0.14300M | -1.19600M | -2.19100M |
| Common stock | 10.35M | 10.35M | 10.35M | 10.35M | 10.35M |
| Capital stock | 10.35M | 10.35M | 10.35M | 10.35M | 10.35M |
| Retained earnings | -58.08600M | -54.02700M | - | -46.66100M | 252.07M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | 284.04M | 308.15M | 0.25M | 0.15M | 0.10M |
| Cash | 14.98M | 10.43M | - | 0.00000M | 1.56M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | - | 1.87M | 0.14M | 1.20M | 2.19M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 14.63M | 12.39M | 32.47M | 39.98M | 20.31M |
| Short term debt | 29.61M | 22.83M | - | - | 21.87M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 29.61M | 22.83M | 32.47M | 39.98M | 21.87M |
| Other stockholder equity | 29.87M | 294.46M | 259.97M | 274.54M | 313.43M |
| Property plant equipment | - | - | - | - | - |
| Total current assets | - | 10.65M | 2.72M | 13.34M | 2.40M |
| Long term investments | 268.92M | 297.51M | 301.90M | 313.43M | 345.34M |
| Net tangible assets | - | - | - | 284.89M | 323.77M |
| Short term investments | - | - | - | - | - |
| Net receivables | 0.07M | 0.11M | 2.72M | 13.34M | 0.84M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 2.06M | 1.87M | 0.14M | 1.20M | 2.19M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 267.28M | 31.48M | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | -297.50700M | -301.90400M | -313.42900M | -345.33600M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | - | 297.51M | 301.90M | 313.43M | 345.34M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
| Investments | - | - | - | - | - |
| Change to liabilities | - | - | - | 0.26M | 1.48M |
| Total cashflows from investing activities | - | - | - | - | - |
| Net borrowings | 7.76M | 24.73M | - | - | - |
| Total cash from financing activities | -23.92500M | -2.19800M | -21.38500M | -16.41300M | 11.99M |
| Change to operating activities | - | - | - | 19.01M | -43.11300M |
| Net income | -1.17000M | 38.88M | 6.93M | -22.32200M | 28.05M |
| Change in cash | 4.55M | 42.91M | 7.50M | -19.66400M | -2.54000M |
| Begin period cash flow | 10.43M | -32.47400M | -39.97600M | -20.31200M | -17.77200M |
| End period cash flow | 14.98M | 10.43M | -32.47400M | -39.97600M | -20.31200M |
| Total cash from operating activities | 28.63M | 45.35M | 27.30M | 1.12M | -14.53300M |
| Issuance of capital stock | - | - | - | 0.00000M | 23.56M |
| Depreciation | - | - | - | - | - |
| Other cashflows from investing activities | - | -50.46300M | - | - | - |
| Dividends paid | 11.20M | 10.77M | 11.41M | 12.88M | 11.56M |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | 0.00900M | 0.01M | - | -0.03300M | -0.78100M |
| Sale purchase of stock | -20.49000M | -16.16000M | -9.97800M | -3.53400M | 23.56M |
| Other cashflows from financing activities | - | - | - | - | - |
| Change to netincome | - | - | - | 4.36M | 4.36M |
| Capital expenditures | 28.63M | 45.35M | 0.00000M | 0.00000M | 0.00000M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 1.77M | -0.73200M | 22.06M | 0.23M | -42.41800M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | 28.03M | 7.21M | -1.69900M | 23.22M | -0.16200M |
| Free cash flow | 28.63M | 45.35M | 27.30M | 1.12M | -14.53300M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (GBX) | Price (GBX) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | |
|---|---|---|---|---|---|---|---|---|
| IBT International Biotechnology Trust plc |
28.00 2.99% | 966.00 | - | 714.29 | 16.40 | 1.20 | 15.60 | |
| GNS Genus PLC |
38.00 1.70% | 2274.00 | 36.08 | 26.18 | 2.53 | 3.46 | 2.92 | 15.38 |
| ONT Oxford Nanopore Technologies Ltd |
5.50 4.09% | 140.00 | - | - | 4.71 | 2.50 | 4.23 | -8.8899 |
| OXB Oxford BioMedica PLC |
28.00 4.90% | 600.00 | - | 208.33 | 4.05 | 7.60 | 4.42 | 308.96 |
| AVCT Avacta Group PLC |
- -% | 70.00 | - | - | 2849.46 | 1929.84 | 2525.51 | -12.0368 |
International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of a product, device or enabling technology and also invests in the therapeutic sub-sector. The fund also prefers to invest in companies with strong growth potential from the development and/or commercialization of either a biotechnology drug candidate, medical device or other enabling technology for medical research. It may also invest in specialty pharmaceuticals and life science tools. These companies can range from small private companies with strong science and people that need development funding, to large, multi-billion dollar biotechnology and medical device companies which have portfolios of products, many of which are already used in hospitals, clinics and pharmacies around the world. It makes majority of its investments in smaller and mid-capitalization quoted companies and seeks to invest up to thirty percent of the Company's assets in unquoted companies, while allowing an exposure of up to forty percent in unquoted companies (at the time of investment and after allowing for valuation write-ups and further follow-on investments). The fund typically invests in the United States, but seeks the best investments worldwide and so may also invest in Western Europe, Australia, and Asia. It typically invests between $1 million and $4 million in its portfolio companies. It exits its unquoted investments through the sale of the
31 Gresham Street, London, United Kingdom, EC2V 7QA
| Name | Title | Year Born |
|---|---|---|
| Ms. Lucy Costa Duarte | Head of Investor Relations | NA |
| Ms. Catherine Elizabeth Bingham M.B.A. | Managing Partner | 1966 |
| Ms. Ailsa Craig | Investment Mang. | NA |
| Mr. Marek Poszepczynski M Sci Eng | Investment Mang. | NA |
| Claire Jackson | Company Sec. | NA |
| Dr. Carl Harald Janson | Lead Investment Mang. | NA |
| Ms. Catherine Elizabeth Bingham M.B.A. | Managing Partner | 1967 |
| Ms. Claire Jackson | Company Secretary | NA |
| Dr. Carl Harald Janson and CEFA, M.D., Ph.D. | Lead Investment Manager | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.